GABA-related psychoactive compound · Fact sheet
Phenibut
Also known as Beta-phenyl-GABA · Fenibut
Phenibut is a psychoactive GABA-related compound associated with dependence, intoxication and potentially severe withdrawal. It is not an FDA-approved anxiety or sleep treatment, and FDA does not recognize it as a dietary ingredient.
What is Phenibut?
Phenibut is structurally related to GABA and has GABA-B-related pharmacology. It is not a peptide.
Phenibut HCl and free-amino-acid products do not establish a clinically validated consumer regimen.
Benefits & claims
Readers encounter Phenibut in discussions of cognition, mood or mental fatigue. The relevant study population and outcome determine whether those claims are supported.
What the evidence supports
- The CDC surveillance report describes sedation, agitation, confusion and serious outcomes among reported exposures.
- Poison-center cases cannot establish how often harms occur among all users.
- Desired relaxation or sleep effects do not establish a favorable treatment benefit-risk balance.
Research areas
- Cognition and memory
- Neurologic or psychiatric research
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for Phenibut. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- Phenibut is structurally related to GABA and has GABA-B-related pharmacology. It is not a peptide.
Formulation differences
- Phenibut HCl and free-amino-acid products do not establish a clinically validated consumer regimen.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Reproducible benefit on everyday function in the intended population
- Long-term safety and clinically important interactions
- Equivalence of nonstandard products to research formulations
Side effects & risks
- Dependence and withdrawal can involve severe agitation, delirium or other serious neurologic symptoms.
- Co-exposure to other sedating substances complicates and may worsen toxicity; product contents may be uncertain.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Limited or unclear evidenceU.S. evidence includes poison-center surveillance and clinical case reports. These document hazards rather than proving an effective anxiety or sleep regimen.
Studies
Original clinical case report; product purity and exposure confirmation were limited.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
Phenibut is not an FDA-approved treatment for the cognitive or mood uses discussed here. Regional use, historical trials and online availability are separate from U.S. drug approval.
No FDA-approved product for this entry
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Reproducible benefit on everyday function in the intended population
- Long-term safety and clinically important interactions
- Equivalence of nonstandard products to research formulations
Summary
Desired relaxation or sleep effects do not establish a favorable treatment benefit-risk balance.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- medical institutionCDC: U.S. phenibut poison-center exposures
Primary national poison-center surveillance, including serious outcomes; not a measure of risk per user.
- fdaFDA: phenibut in dietary supplements
FDA states phenibut does not meet the statutory definition of a dietary ingredient.
- pubmedPhenibut intoxication and prolonged withdrawal
Original clinical case report; product purity and exposure confirmation were limited.